Changes in patterns of hospitalized children with varicella and of associated varicella genotypes after introduction of varicella vaccine in Australia

Pediatric Infectious Disease Journal

Volumn 32, Issue 5, 2013, Pages 530-537

  Marshall, Helen S ^a,b   McIntyref, Peter ^c,d,e   Richmond, Peter ^f   Buttery, Jim P ^g   Royle, Jenny A ^g   Gold, Michael S ^b   Wood, Nicholas ^c,d,e   Elliott, Elizabeth J ^c,e,h   Zurynski, Yvonne ^e,h   Toi, Cheryl S ⁱ   Dwyer, Dominic E ^e,i   Booy, Robert ^c,d,e  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d National Centre for Immunization Research and Surveillance Sydney   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h Australian Paediatric Surveillance Unit   (Australia)

ⁱ WESTMEAD HOSPITAL   (Australia)

Author keywords

Hospitalization; Immunization; Immunocompromised; Pediatric; Varicella

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE; FAMCICLOVIR; VALACICLOVIR;

ADOLESCENT; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; BACTERIAL ARTHRITIS; CHICKENPOX; CHILD; CLINICAL FEATURE; DEHYDRATION; DIPLOPIA; DISEASE SURVEILLANCE; ENCEPHALITIS; FEMALE; GASTROENTERITIS; GENOTYPE; GUILLAIN BARRE SYNDROME; HERPES ZOSTER; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFANT; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MYELITIS; ORBIT CELLULITIS; OSTEOMYELITIS; OTITIS MEDIA; PANCREATITIS; PERICARDIAL EFFUSION; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PYELONEPHRITIS; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SEIZURE; SKIN INFECTION; TERTIARY HEALTH CARE; VIRUS STRAIN;

ADOLESCENT; AUSTRALIA; CHI-SQUARE DISTRIBUTION; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HOSPITALIZATION; HUMANS; INFANT; MALE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES;

EID: 84879103192     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31827e92b7     Document Type: Article

References (36)

1. Arvin A, Abendroth A. VZV: Immunobiology and host response. In: Arvin A, Campadelli-Fiume G, Mocarski E, et al, eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge, UK: Cambridge University Press; 2007:700-712.
2. Choo PW, Donahue JG, Manson JE, et al. The epidemiology of varicella and its complications. J Infect Dis. 1995;172:706-712.
3. Atkinson W, Harrison S, Wolfe C, et al, eds. Varicella. Epidemiology and Prevention of Vaccine-Preventable Diseases. 7th ed. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2002.
4. Ziebold C, von Kries R, Lang R, et al. Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics. 2001;108:E79.
5. Khandaker G, Marshall H, Peadon E, et al. Congenital and neonatal varicella: Impact of the national varicella immunisation program in Australia. Arch Dis Child. 2011;96:453-456.
6. Chant KG, Sullivan EA, Burgess MA, et al. Varicella-zoster virus infection in Australia. Aust NZ J Public Health. 1998;22:413-418.
7. National Health, Medical Research Council. The Australian Immunisation Handbook. 9th ed. Canberra, Australia: Australian Government Publishing Service; 2008.
8. Mclntyre P, Gidding H, Gilmour R, et al. Vaccine preventable diseases and immunisation coverage in Australia, 1999-2000. Commun Dis Intell. 2002;26:S1-111.
9. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-611.
10. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005;352:450-458.
11. Carville KS, Riddell MA, Kelly HA. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine. 2010;28:2532-2538.
12. Carapetis JR, Russell DM, Curtis N. The burden and cost of hospitalised varicella and zoster in Australian children. Vaccine. 2004;23:755-761.
13. Scheifele DW, Halperin SA, and members of the Health Canada/CPS Immunization Monitoring Program, Active (IMPACT). A model of active surveillance of vaccine safety. Sem Fed Infect Dis. 2003;14:213-219.
14. Pym M, Adams J, Booy R, et al. The development and trial of Paediatric Active Enhanced Disease Surveillance (PAEDS): a new surveillance mechanism for Australia. J Paediatr Child Health. 2008;44:A16.
15. Peadon E, Burgner D, Nissen M, et al. Case for varicella surveillance in Australia. J Paediatr Child Health. 2006;42:663-664.
16. LaRussa P, Steinberg S, Arvin A, et al. Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. J Infect Dis. 1998;178(suppl 1):S64-S66.
17. Toi CS, Dwyer DE. Differentiation between vaccine and wild-type varicella-zoster virus genotypes by high-resolution melt analysis of single nucleotide polymorphisms. J Clin Virol. 2008;43:18-24.
18. Australian Government. Department of Human Services. Australian Childhood Immunisation Register. Available at: http://www.humanservices.gov.au/customer/ services/medicare/australian-childhood-immunisation-register. Accessed August 2007.
19. Toi CS, Dwyer DE. Prevalence of varicella-zoster virus genotypes in Australia characterized by high-resolution melt analysis and ORF22 gene analyses. J Med Microbiol. 2010;59(pt 8):935-940.
20. Breuer J, Grose C, Norberg P, et al. A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008. J Gen Virol. 2010: 91: 821-828.
21. Hull B, Dey A, Mahajan D, et al. Immunisation coverage annual report, 2009. Commun Dis Intell. 2011;35:132-148.
22. van Lier A, van der Maas NA, Rodenburg GD, et al. Hospitalization due to varicella in the Netherlands. BMC Infect Dis. 2011;11:85.
23. Wiegering V, Schick J, Beer M, et al. Varicella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis. BMC Pediatr. 2011;11:31.
24. Ross AH, Lechner E, Reitman G. Modification of chickenpox in family contacts by administration of gammaglobulin. N Engl J Med. 1962; 267: 369-376.
25. Schmidt-Chanasit J, Sauerbrei A. Evolution and world-wide distribution of varicella-zoster virus clades. Infect Genet Evol. 2011;11:1-10.
26. Loparev VN, Rubtcova EN, Bostik V, et al. Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J Virol. 2007;81:12758-12765.
27. Peters GA, Tyler SD, Carpenter JE, et al. The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation. J Virol. 2012;86:10695-10703.
28. Vazquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955-960.
29. Kuter B, Matthews H, Shinefield H, et al.; Study Group for Varivax. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132-137.
30. Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics. 2006;117:e1070-e1077.
31. Macartney K, McIntyre P Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev. 2008;16:CD001833.
32. Wutzler P, Knuf M, Liese J. Varicella: Efficacy of two-dose immunization in childhood. Dtsch Arztebl Int. 2008;105:567-572.
33. Shapiro ED, Vazquez M, Esposito D, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis. 2011;203:312-315.
34. Marshall H, Ryan P, Roberton D Uptake of varicella vaccine - a cross sectional survey of parental attitudes to nationally recommended but unfunded varicella immunisation. Vaccine. 2005;23:5389-5397.
35. Marshall H, Ryan P, Roberton D, et al. Varicella immunisation practice: Implications for provision of a recommended, non-funded vaccine. J Paediatr Child Health. 2009;45:297-303.
36. Gutzeit C, Raftery MJ, Peiser M, et al. Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction. J Immunol. 2010;185:488-497.